Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OVA BiP peptide (also referred to as the OVA-BiP hybrid peptide) is a synthetic chimeric peptide that combines an immunodominant epitope from ovalbumin (OVA) with a binding motif derived from the immunoglobulin heavy chain-binding protein (BiP). The BiP motif enables the hybrid to bind heat shock proteins such as HSP70. This complex formation enhances antigen presentation and stimulates robust antigen-specific CD8+ T cell responses in vitro and in vivo. Immunization with the OVA-BiP–HSP70 complex has been shown to induce strong cytotoxic T lymphocyte (CTL) responses and provide significant protection against tumor challenge in mouse models. The mechanism leverages improved delivery of antigenic peptides via HSPs, facilitating efficient cross-presentation by dendritic cells and activation of cellular immunity[2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OVA BiP peptide.